Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Anticancer Res. 2021 Jan;41(1):533-541. doi: 10.21873/anticanres.14805.
BACKGROUND/AIM: We compared the efficacy and safety of second-line FOLFIRI with bevacizumab (Bmab) or aflibercept (AFL) in patients with unresectable metastatic colorectal cancer (mCRC) to clarify selection criteria for anti-angiogenic agents.
The subjects were patients with mCRC who received second-line FOLFIRI in combination with Bmab or AFL. The primary endpoint was median overall survival (OS). Secondary endpoints were median time to treatment failure (TTF), overall response rate (ORR) and incidence of adverse events.
Data from 26 patients in the Bmab group and 19 in the AFL group were analyzed. Median OS was slightly longer in the AFL group compared to the Bmab group, whereas median TTF was similar. ORR tended to be higher in the AFL group. The incidence of ≥grade 2 diarrhea and proteinuria was significantly higher in the AFL group than the Bmab group.
In patients given combination treatment with FOLFIRI for second-line treatment of mCRC, AFL can increase response rates compared to Bmab, which may contribute to longer survival.
背景/目的：我们比较了二线 FOLFIRI 联合贝伐珠单抗（Bmab）或阿柏西普（AFL）治疗不可切除转移性结直肠癌（mCRC）患者的疗效和安全性，以明确抗血管生成药物的选择标准。
本研究对象为接受二线 FOLFIRI 联合 Bmab 或 AFL 治疗的 mCRC 患者。主要终点为中位总生存期（OS）。次要终点为中位无进展生存期（TTF）、总缓解率（ORR）和不良事件发生率。
Bmab 组和 AFL 组分别有 26 例和 19 例患者纳入分析。AFL 组的中位 OS 略长于 Bmab 组，而中位 TTF 相似。AFL 组的 ORR 倾向于更高。≥2 级腹泻和蛋白尿的发生率在 AFL 组明显高于 Bmab 组。
对于接受 FOLFIRI 联合治疗作为二线治疗 mCRC 的患者，AFL 可提高缓解率，从而可能延长生存时间。
